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We improved the migration and survival of chimeric antigen receptor (CAR)-modified T cells in solid tumors by
combining CAR-T cells with an armed oncolytic virus. Local delivery of the chemokine RANTES and the cytokine IL-15 by
the oncolytic virus enhanced the trafficking and persistence of the CAR-T cells, resulting in improved antitumor effects.
Adoptive transfer of T cells modified to
express chimeric antigen receptors (CARs)
has had clinical success in B-lymphocyte
derived malignancies.1 However, the clini-
cal efficacy of CAR-T cells remains lim-
ited in solid tumors. This unfavorable
outcome could be due to the insufficient
migration of the infused T cells to the
tumor site as well as to the immunosup-
pressive characteristics of the tumor envi-
ronment that inhibits the effector
function and proliferation of those few T
cells that do reach the tumor.
CAR molecules have been further engi-
neered to express co-stimulatory endodo-
mains such as those derived from CD28
and tumor necrosis factor receptor super-
family member 9 (TNFRSF9, better
known as 4–1BB) to promote T-cell pro-
liferation and persistence upon encounter-
ing tumor cells. CD28 has proven
effective in inducing CAR-T cell expan-
sion in B-cell malignancies.2,3 The incor-
poration of 4–1BB seems, however, to
sustain more robust engraftment of
CD19-specific CAR-T cells.1 The incor-
poration of these co-stimulatory molecules
in CARs targeting antigens expressed by
solid tumors is anticipated to play a simi-
larly crucial role.
CAR-T cells targeting CD19 seem to
traffic physiologically to the bone mar-
row and lymph nodes, the primary sites
of hematologic malignancies.1,3 In
addition, they can encounter both nor-
mal B lymphocytes and leukemic cells
directly in the circulation. By contrast,
T-cell migration remains a relevant prob-
lem for solid tumors. For instance, while
tumor-infiltrating T lymphocytes (TILs)
isolated from tumor biopsies and
expanded ex vivo show dramatic migra-
tion to melanoma lesions, polyclonal T
lymphocytes isolated from the peripheral
blood and engineered with a T-cell
receptor seem less effective. This dispar-
ity suggests that TILs and peripheral
blood T cells may have a different pattern
of homing molecules.4 If the current
CAR-T cell studies in solid tumors such
as neuroblastoma, prostate cancer, pan-
creatic cancer, and mesothelioma reveal
suboptimal migration, countermeasures
to increase T-cell migration should be
applied. Radiation or chemotherapy
before the infusion of CAR-T cells in
patients with solid tumors may favorably
alter the pattern of T-cell migration.
However, several preclinical models have
already demonstrated that engineering
CAR-T cells to express chemokine recep-
tors that pair with chemokines produced
by tumor cells is a strategy that can over-
come the trafficking issue.5
When CAR-T cells reach the tumor
bed in a sufficient number, tumor-
associated inhibitory mechanisms are there
to shutdown effective immune responses.
In the treatment of small tumors, infusion
of CAR-T cells after chemo or radiother-
apy may partially reduce the impact of
these inhibitory mechanisms. In addition,
the recent introduction of antibodies that
block T-cell inhibitory mechanisms, such
as those abrogating the immune check-
point CTLA-4 and PD1-PDL-1 pathways,
shows great potential. Combinations of
CAR-T cell therapies with these antibodies
are anticipated to make a substantial dif-
ference in the near future. Similarly to the
genetic modification of CAR-T cells
aimed to express specific chemokine recep-
tors, a plethora of genetic modifications
has been proposed to increase the fitness
of CAR-T cells within the tumor environ-
ment.5 Some of the proposed modifica-
tions are currently under clinical
investigation. Although each single modi-
fication seems to have specific beneficial
effects, multiple mechanisms of resistance
can be developed by tumors. T cells must
accomplish simultaneously optimal traf-
ficking and persistence, while also retain-
ing an acceptable safety profile. In our
recent study,6 we developed an engineer-
ing strategy where an armed oncolytic
virus (OV), another single biological
agent, creates a favorable tumor environ-
ment for CAR-T cells.
OVs selectively infect, lyse and repli-
cate in malignant cells without affecting
non-malignant cells.7 In addition, OVs
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have sufficient cargo capacity to insert
multiple ectopic genes that can be benefi-
cial for CAR-T cells. To investigate the
effect of combining armed OV and CAR-
T cells, we choose the neuroblastoma
model since this tumor model has been
previously targeted with CAR-T cells spe-
cific for the GD2 antigen.8 We also
selected an oncolytic adenovirus
(Ad5D24) that has been extensively used
in the clinic. We exploited the tropism of
the OV for the tumor cells and engineered
the virus to express both a chemokine and
a growth factor for the T cells in order to
achieve optimal trafficking of the engi-
neered T cells to the tumor site and to
generate a cytokine milieu that sustains
T-cell growth and survival. Therefore, we
armed Ad5D24 with chemokine (C-C
motif) ligand 5 (CCL5, better known as
RANTES) and interleukin (IL)-15
(Fig. 1), 2 immunomodulatory molecules
selected on the basis of both clinical and
preclinical data. RANTES is also a very
potent chemokine and its receptors are
maintained in T cells expanded ex vivo.
Using this strategy, we anticipated that
tumor cells, regardless of their tissue ori-
gin, could be forced to ectopically express
RANTES after infection with the armed
OV. We hypothesized that this strategy
would promote efficient migration of the
infused CAR-T cells without the need to
select a chemokine/chemokine receptor
pathway specific for each single tumor
type. The cytokine IL-15 was selected for
its multiple beneficial effects on T cells,
and its overall ability to increase T-cell
antitumor functions. In our experimental
design, we demonstrated that neuroblas-
toma cells infected with Ad5D24.
RANTES.IL-15 produce functional levels
of RANTES and IL-15 both in vitro and
in vivo, while the cytopathic effect of the
virus is conserved. In a xenogenic mouse
model, combined therapy with Ad5D24.
RANTES.IL-15 and GD2.CAR-T cells
significantly enhanced the survival of mice
as compared with either of the mono-
therapies. Furthermore, both RANTES
and IL-15 released by the armed OV were
predominantly detected at the tumor site,
rather than in the serum, indicating a pref-
erential local expression of both factors.
This strategy thereby circumvented the
toxicities associated with systemic admin-
istration of cytokines.6
In conclusion, our preclinical study
demonstrates that optimal trafficking and
survival of CAR-T cells can be obtained in
solid tumors by engineering an OV with-
out compromising its cytopathic effect. In
principle, similar genetic modifications
can be applied to OVs such as vaccinia
viruses and measles virus that have been
administered intravenously into patients to
treat metastatic tumors already.9,10 Arming
these viruses using this proposed strategy
will not only favor the rapid recruitment of
tumor-specific T cells to the
primary lesions so infected
but will also enhance the
spread of the virus to other
tumor cells, thus amplifying
the therapeutic effect of the
viruses. In addition, consid-
ering the cargo capacity of
these viruses, other relevant
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Figure 1. Combined therapy with CAR-T cells and Ad5D24 armed with RANTES and IL-15. Oncolytic viruses (OVs)
selectively infect and lyse tumor cells, and then spread to neighboring tumor cells. Virus-infected tumor cells release
both proteins and undergo apoptosis. The chemokine RANTES attracts circulating chimeric antigen receptor (CAR)
modified T cells (CAR-T) to the virus infected tumor site and migrated CAR-T cells persist by virtue of interleukin 15
(IL-15) and specific antigen stimulation.
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